MX2020006388A - Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. - Google Patents
Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea.Info
- Publication number
- MX2020006388A MX2020006388A MX2020006388A MX2020006388A MX2020006388A MX 2020006388 A MX2020006388 A MX 2020006388A MX 2020006388 A MX2020006388 A MX 2020006388A MX 2020006388 A MX2020006388 A MX 2020006388A MX 2020006388 A MX2020006388 A MX 2020006388A
- Authority
- MX
- Mexico
- Prior art keywords
- diagnosis
- prognosis
- cornea
- subject
- biomarkers
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
La invención se refiere al campo de los métodos de diagnóstico y pronóstico de patologías moleculares. En particular, la invención se refiere a métodos para determinar el diagnóstico de una enfermedad ectásica de la córnea en un sujeto, para determinar el riesgo de desarrollar una enfermedad ectásica de la córnea en un sujeto, para determinar el desenlace clínico de un sujeto que padece una enfermedad ectásica de la córnea y para seleccionar un sujeto que va a tratarse con una terapia para una enfermedad ectásica de la córnea basándose en la determinación de los niveles de expresión de los marcadores TLR2 y/o TLR4. La invención también se refiere al uso de TLR2 y/o TLR4 como marcadores de diagnóstico y pronóstico para una enfermedad ectásica de la córnea.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382060.0A EP3056906A1 (en) | 2015-02-16 | 2015-02-16 | Biomarkers for diagnosis and prognosis of corneal ectasia |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006388A true MX2020006388A (es) | 2020-09-17 |
Family
ID=52589323
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010516A MX2017010516A (es) | 2015-02-16 | 2016-02-16 | Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea. |
MX2020006388A MX2020006388A (es) | 2015-02-16 | 2017-08-15 | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010516A MX2017010516A (es) | 2015-02-16 | 2016-02-16 | Biomarcadores para el diagnóstico y pronóstico de trastornos ectáticos de la córnea. |
Country Status (13)
Country | Link |
---|---|
US (2) | US10914746B2 (es) |
EP (3) | EP3056906A1 (es) |
JP (1) | JP6904908B2 (es) |
KR (1) | KR102495060B1 (es) |
AU (1) | AU2016221761A1 (es) |
CA (1) | CA2975951C (es) |
DK (1) | DK3259599T3 (es) |
ES (1) | ES2764456T3 (es) |
HK (1) | HK1248810A1 (es) |
MX (2) | MX2017010516A (es) |
PT (1) | PT3259599T (es) |
SG (1) | SG11201706249RA (es) |
WO (1) | WO2016131840A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6707239B1 (ja) * | 2019-03-13 | 2020-06-10 | 株式会社中京メディカル | 円錐角膜判定装置及びプログラム |
KR102287259B1 (ko) * | 2019-08-27 | 2021-08-06 | 주식회사 비쥬웍스 | 원추 각막 진단 보조 시스템 및 이를 이용하는 방법 |
CN113009158B (zh) * | 2021-04-30 | 2023-07-25 | 天津市眼科医院 | 中高度近视的辅助诊断标记物及其用途 |
US11406531B1 (en) * | 2021-07-24 | 2022-08-09 | Peter S. Hersh | Method for the amelioration of ectatic and irregular corneal disorders |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7370969B2 (en) * | 2004-03-31 | 2008-05-13 | Nidek Co., Ltd. | Corneal topography analysis system |
GB0601959D0 (en) * | 2006-01-31 | 2006-03-15 | King S College London | Sepsis test |
US20070248970A1 (en) * | 2006-03-24 | 2007-10-25 | Eye Birth Defects Research Foundation | Compositions and methods for detecting keratoconus |
WO2011066621A1 (en) * | 2009-12-02 | 2011-06-09 | The University Of Sydney | Diagnostic and therapeutic methods for corneal ectasia following refractive surgery, keratoconus or pellucid degeneration |
KR20130027281A (ko) * | 2011-09-07 | 2013-03-15 | (주)에스엘에스 | 원추각막 검사 방법 및 키트 |
WO2013107826A2 (en) * | 2012-01-17 | 2013-07-25 | Institut Pasteur | Use of cellular biomarkers expression to diagnose sepsis among intensive care patients |
WO2014106833A1 (en) * | 2013-01-07 | 2014-07-10 | Singapore Health Services Pte Ltd | A process for identification of biomarkers for keratoconus progression |
-
2015
- 2015-02-16 EP EP15382060.0A patent/EP3056906A1/en not_active Withdrawn
-
2016
- 2016-02-16 ES ES16705123T patent/ES2764456T3/es active Active
- 2016-02-16 DK DK16705123.4T patent/DK3259599T3/da active
- 2016-02-16 CA CA2975951A patent/CA2975951C/en active Active
- 2016-02-16 SG SG11201706249RA patent/SG11201706249RA/en unknown
- 2016-02-16 EP EP19200400.0A patent/EP3608675A1/en not_active Withdrawn
- 2016-02-16 WO PCT/EP2016/053293 patent/WO2016131840A1/en active Application Filing
- 2016-02-16 US US15/551,386 patent/US10914746B2/en active Active
- 2016-02-16 KR KR1020177025898A patent/KR102495060B1/ko active IP Right Grant
- 2016-02-16 MX MX2017010516A patent/MX2017010516A/es active IP Right Grant
- 2016-02-16 PT PT167051234T patent/PT3259599T/pt unknown
- 2016-02-16 AU AU2016221761A patent/AU2016221761A1/en not_active Abandoned
- 2016-02-16 EP EP16705123.4A patent/EP3259599B1/en active Active
- 2016-02-16 JP JP2017561040A patent/JP6904908B2/ja active Active
-
2017
- 2017-08-15 MX MX2020006388A patent/MX2020006388A/es unknown
-
2018
- 2018-06-27 HK HK18108283.9A patent/HK1248810A1/zh unknown
-
2021
- 2021-01-11 US US17/145,549 patent/US20210132084A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2975951A1 (en) | 2016-08-25 |
US20210132084A1 (en) | 2021-05-06 |
HK1248810A1 (zh) | 2018-10-19 |
CA2975951C (en) | 2023-02-14 |
ES2764456T3 (es) | 2020-06-03 |
AU2016221761A1 (en) | 2017-09-28 |
EP3608675A1 (en) | 2020-02-12 |
PT3259599T (pt) | 2020-01-27 |
DK3259599T3 (da) | 2020-01-13 |
EP3056906A1 (en) | 2016-08-17 |
KR102495060B1 (ko) | 2023-02-02 |
EP3259599B1 (en) | 2019-10-02 |
SG11201706249RA (en) | 2017-08-30 |
US20180067128A1 (en) | 2018-03-08 |
US10914746B2 (en) | 2021-02-09 |
WO2016131840A1 (en) | 2016-08-25 |
MX2017010516A (es) | 2018-06-15 |
JP6904908B2 (ja) | 2021-07-21 |
KR20170138400A (ko) | 2017-12-15 |
EP3259599A1 (en) | 2017-12-27 |
JP2018510651A (ja) | 2018-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006075A (es) | Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer. | |
MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
MX2018012580A (es) | Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia. | |
WO2016077366A8 (en) | Therapeutic and diagnostic methods for il-33-mediated disorders | |
MX2020006388A (es) | Biomarcadores para el diagnostico y pronostico de trastornos ectaticos de la cornea. | |
MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
PH12020551683A1 (en) | Biomarkers for graft-versus-host disease | |
MX351428B (es) | Métodos in vitro para correlacionar el nivel de sr2 solubre y la eficiencia de terapia de ejercicio en un sujeto que tiene una enfermedad cardiovascular. | |
MX2016012285A (es) | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. | |
MX2015009392A (es) | Biomarcadores de terapia de combinacion anti-tnf y anti-il17 para enfermedades inflamatorias. | |
EA201790211A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака | |
MX2017004742A (es) | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. | |
NZ729773A (en) | Biomarkers for disease progression in melanoma | |
EP3495502A3 (en) | Biomarkers for premature birth | |
EA201700123A1 (ru) | Способ прогнозирования варианта лекарственного препарата для лечения депрессии | |
EA201890649A1 (ru) | Новые биомаркеры и способы лечения рака | |
NZ730664A (en) | A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases | |
EA202090673A1 (ru) | Стратификация генотипа при лечении и профилактике диабета | |
WO2015036643A3 (es) | Marcador para predecir metástasis del cáncer de mama | |
MX2017014540A (es) | Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus. | |
WO2015181555A8 (en) | Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent | |
EA201491780A1 (ru) | Мутанты c-raf, придающие резистентность к ингибиторам raf | |
EP4289970A3 (en) | Circulating serum microrna biomarkers and methods for alzheimer's disease diagnosis | |
EA201891693A1 (ru) | Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови | |
WO2017059276A3 (en) | Therapeutic and diagnostic methods for autoimmune diseases and/or inflammation |